

SUPPLEMENTARY MATERIAL

Table 1. Clinical, laboratory and psychiatric characteristics of HAE patients with C1INH deficiency or FXII mutation

Patients	HAE type	Age/Sex	long-term prophylactic care	Annual attack (n)	Comorbidities	COVID-19 symptoms	HAE attack localization	Pulmonary involvement	COVID-19 treatment	D-dimer $\mu\text{g}/\text{ml}$ (0-440)	CRP mg/dl (0-5)	Lymphocyte $10^3/\mu\text{l}$ (0.6-3.4)	Fear during COVID-19	Fear, now	CAS	Psychiatric impaired function
1	C1INH-HAE	28 M	On-demand	24	No	Back pain, cough, dyspnea, myalgia	Hands, leg	Bilateral diffuse ground-glass opacities	Favipiravir Heparin Methyl-prednisolon 1mg/kg	3260	8.3	2.4	6	10	5	+
2	C1INH-HAE	51 F	On-demand	50	Obesity	Back pain, sore throat, myalgia	Abdomen, lips, neck, shoulder	None	Favipiravir Heparin	9145	3	2.8	10	7	2	-
3	C1INH-HAE	43 F	On-demand	40	No	Chills, cough	Eyelid, leg, abdomen, heel	NA	Favipiravir	NA	NA	NA	7	5	1	-
4	C1INH-HAE	48 F	On-demand	38	No	Headache, myalgia	Abdomen, lips, chin	None	Favipiravir	620	5.1	1.5	5	5	1	-
5	C1INH-HAE	35 M	On-demand	20	No	Anosmia, ageusia, fever, headache	Soles of the feet	None	Favipiravir Heparin	1520	9.7	1.7	1	3	0	-
6	C1INH-HAE	25 F	On-demand	52	No	Fever, ageusia, anosmia, cough	None	Nonhomogeneous infiltration in the left lower zone	Favipiravir Aspirin 100mg/qd	840	9.9	2.3	5	5	0	-
7	C1INH-HAE	43 F	Danazol	24	Diabetes	Headache, back pain, myalgia anosmia	Abdomen	NA	Favipiravir	NA	NA	NA	10	8	6	+
8	C1INH-HAE	27 F	Danazol	14	No	Sore throat, headache, cough fever	Abdomen	NA	Favipiravir	NA	NA	NA	6	8	0	-

9	C1INH-HAE	29 F	Danazol	17	Obesity	Sore throat, dysgeusia	None	NA	Favipiravir	440	2	2.7	10	6	1	-
10	C1INH-HAE	55 M	Danazol	6	Hypertension, diabetes	Cough, chest pain on inspiration	None	Bilateral subpleural patchy ground-glass opacities	Favipiravir	450	15.9	1.1	2	2	0	-
11	FXII-HAE	23 F	Tranexamic acid	6	No	Headache backpain, myalgia	None	NA	Favipiravir hydroxychloroquine	NA	NA	NA	8	5	2	-

C1INH-HAE, Hereditary angioedema with C1INH deficiency; FXII-HAE, hereditary angioedema with FXII mutation; F, female; M, male; NA, not applicable; Fear, Fear related to COVID-19; CAS, Coronavirus Anxiety Scale⁴

Table 2. Comparison of the psychiatric variables of the patients who had an HAE attack during COVID-19 and the ones who had not an attack

<i>Variables</i>	<i>Attack + (n=7)</i>	<i>No Attack (n=4)</i>	<i>Total (n=11)</i>
Fear related to COVID-19, when they get the diagnosis of COVID-19, Median (minimum-maximum)*	6 (1-10)	6.75 (2-10)	6 (1-10)
Fear related to COVID-19, now, Median (minimum-maximum)*	7 (3-10)	5 (2-6)	5 (2-10)
Compliance to the personal protective measures against coronavirus, before acquiring COVID-19, Median (minimum-maximum)*	7.5 (6-8)	8.5 (5-9)	8 (5-9)
Compliance to the personal protective measures against coronavirus, now, Median (minimum-maximum)*	9 (7-10)	8,5 (8-9)	8.55 (7-10)
Coronavirus anxiety scale score, Mean±SD	2.14±2.41	0.75±0.96	1.64±2.06
Thinking that HAE would lead to a severe COVID-19 presentation, n (%)	6 (85.7)	3 (75)	9 (81.8)
Thinking that COVID-10 would trigger HAE attacks, n (%)	7 (100)	3 (75)	10 (90.9)
Psychologically disturbed during COVID-19, n (%)	6 (85.7)	4 (100)	10 (90.9)
Still continuing psychological impaired functionality, n (%)	2 (28.6)	0 (0)	2 (18.2)

*Participants are required to rate the variable in the range of 1-10, while 1 indicates the lowest intensity, 10 indicates the highest
SD: standard deviation